SHPH: Shuttle Pharmaceuticals Holdings Net earnings per share (EPS TTM)

Net income per share over the last four quarters reflects the asset's dynamics, with the indicator reaching -31.01. Shuttle Pharmaceuticals (SHPH) faces logistical risks and regulatory pressure during testing. Shuttle Pharmaceuticals is developing agents to enhance radiation impact on tumors while minimizing health damage. The project currently relies on institutional support while awaiting FDA approval to launch commercial sales.

This indicator measures the rolling annual earnings per common share, excluding the impact of security issuance. For Shuttle Pharmaceuticals (SHPH), annual net income per share reflects a stage of deep losses due to a lack of sales. The negative price action on the chart confirms the cost-intensive nature of developing radiotherapeutic drugs. Investors should consider the risk of the business being entirely dependent on external financing. Current metrics indicate that the asset is highly speculative.